3.8 Article

Precision oncology How can high-quality healthcare remain affordable for all in the face of diagnostic and therapeutic costs?

期刊

UROLOGE
卷 60, 期 1, 页码 3-7

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00120-020-01416-1

关键词

Oncology; Evidence based medicine; Network medicine; Clinical efficacy; Urological neoplasms

向作者/读者索取更多资源

Medicine is becoming increasingly precise, particularly in oncology. The shift from a one-drug-fits-all model to an individualized biomarker-driven approach facilitates the transition from efficacy to effectiveness. Ensuring end-to-end precision from diagnostics to real-world evidence is crucial in achieving high-quality, affordable precision medicine for all in the future.
Medicine is becoming increasingly precise. This is particularly evident in the field of pharmaceuticals and especially in oncology. Driven by the steadily growing understanding of biomedical interrelationships and the resulting increase in precision, we are currently experiencing a paradigm shift from a one-drug-fits-all model towards an individualized biomarker-driven approach. This essentially enables the transition from efficacy to effectiveness. In order to ensure that the promise of high-quality, affordable precision medicine for all remains valid in the future, the step from efficacy in clinical studies to effectiveness in the practice of care is crucial in the next decade. This will be achieved with end-to-end precision from diagnostics to real-world evidence.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据